European Nuclear Medicine/Radiopharmaceuticals Market Will be Worth $1.62 Billion by 2020

PUNE, India, November 6, 2015 /PRNewswire/ --

According to a new market research report "European Nuclear Medicine/Radiopharmaceuticals Market by Type {Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)}, Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020", published by MarketsandMarkets, This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period 2015 to 2020.

Browse 145 market data Tables and 60 Figures spread through 197 Pages and in-depth TOC on "European Nuclear Medicine Market "

http://www.marketsandmarkets.com/Market-Reports/european-nuclear-medicine-radiopharmaceuticals-market-1107.html

Early buyers will receive 10% customization on this report. 

This report studies the European Nuclear Medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. The European Nuclear Medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country.

Based on type, the European Nuclear Medicine/radiopharmaceuticals market is categorized into diagnostic and therapeutic radioisotopes. In 2015, the diagnostic segment accounts for a major share of the European Nuclear Medicine/radiopharmaceuticals market. The diagnostic radiopharmaceuticals market is further segmented into SPECT and PET radioisotopes. In 2015, the SPECT segment accounts for the largest share of the European Nuclear Medicine/radiopharmaceuticals diagnostic market. The therapeutic radiopharmaceuticals market is further segmented into beta emitters, alpha emitters, and brachytherapy. In 2015, the beta emitters segment accounts for the largest share of the European Nuclear Medicine/radiopharmaceuticals therapeutic market.

Based on application, the European Nuclear Medicine/radiopharmaceuticals market is segmented into SPECT, PET, and therapeutic applications. In 2015, the cardiology application accounts for the largest share of European Nuclear Medicine SPECT market. The PET market is dominated by oncology applications and therapeutic market is dominated by thyroid applications.

On the basis of country, the market is divided into Germany, France, Italy, U.K., Spain, Russia, and the Rest of Europe (RoE). The Rest of Europe comprises Sweden, Switzerland, Poland, Denmark, The Netherlands, and Belgium, among others. In 2015, Germany accounts for the largest share of the European Nuclear Medicine/radiopharmaceuticals market, followed by France, Italy, and U.K.

Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.

Get The PDF Brochure Of This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=1107

Some of the major players in the European Nuclear Medicine Market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

Browse Related Reports: 

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020.

http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

Nuclear Medicine Equipment Market by Product (SPECT (Hybrid SPECT, Standalone SPECT), hybrid PET, & Planar Scintigraphy), Application (Cardiology, Oncology & Neurology) & by End user (Hospitals, Imaging Centers) - Global Forecasts to 2020.

http://www.marketsandmarkets.com/Market-Reports/nuclear-medicine-equipment-market-242495651.html

About MarketsandMarkets: 

MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
Unit No. 802, 8th Floor, 
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune - 411013, 
Maharashtra, India.
Tel: +1-888-6006-441.
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets